Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 35

2.

Delusional misidentification in Parkinson's disease: report of two cases and a review.

Hermanowicz N.

Postgrad Med. 2018 Mar;130(2):280-283. doi: 10.1080/00325481.2018.1411161. Epub 2017 Dec 13. Review.

PMID:
29185820
3.

The Emerging Role of Pimavanserin in the Management of Parkinson's Disease Psychosis.

Hermanowicz N, Alva G, Pagan F, Espay AJ, Patel A, Madrid KC, Kremens D, Kenney J, Arquette S, Tereso G, Lopes M, Farnum C.

J Manag Care Spec Pharm. 2017 Jun;23(6-b Suppl):S2-S8. doi: 10.18553/jmcp.2017.23.6-b.s2. Review.

4.

A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease.

McGarry A, McDermott M, Kieburtz K, de Blieck EA, Beal F, Marder K, Ross C, Shoulson I, Gilbert P, Mallonee WM, Guttman M, Wojcieszek J, Kumar R, LeDoux MS, Jenkins M, Rosas HD, Nance M, Biglan K, Como P, Dubinsky RM, Shannon KM, O'Suilleabhain P, Chou K, Walker F, Martin W, Wheelock VL, McCusker E, Jankovic J, Singer C, Sanchez-Ramos J, Scott B, Suchowersky O, Factor SA, Higgins DS Jr, Molho E, Revilla F, Caviness JN, Friedman JH, Perlmutter JS, Feigin A, Anderson K, Rodriguez R, McFarland NR, Margolis RL, Farbman ES, Raymond LA, Suski V, Kostyk S, Colcher A, Seeberger L, Epping E, Esmail S, Diaz N, Fung WL, Diamond A, Frank S, Hanna P, Hermanowicz N, Dure LS, Cudkowicz M; Huntington Study Group 2CARE Investigators and Coordinators.

Neurology. 2017 Jan 10;88(2):152-159. doi: 10.1212/WNL.0000000000003478. Epub 2016 Dec 2.

5.

Clinical utility of DaTscan™ imaging in the evaluation of patients with parkinsonism: a US perspective.

Isaacson SH, Fisher S, Gupta F, Hermanowicz N, Kremens DE, Lew MF, Marek K, Pahwa R, Russell DS, Seibyl J.

Expert Rev Neurother. 2017 Mar;17(3):219-225. doi: 10.1080/14737175.2017.1256205. Epub 2016 Nov 23. Review.

PMID:
27813429
6.

The Effect of Gabapentin Enacarbil on Pain Associated with Moderate-to-Severe Primary Restless Legs Syndrome in Adults: Pooled Analyses from Three Randomized Controlled Trials.

Hermanowicz N, Ellenbogen A, Irving G, Buchfuhrer M, Jaros MJ, Shang G, Kim R.

CNS Drugs. 2016 May;30(5):443-54. doi: 10.1007/s40263-016-0333-8.

PMID:
27095237
7.

The safety, tolerability and efficacy of pimavanserin tartrate in the treatment of psychosis in Parkinson's disease.

Hermanowicz S, Hermanowicz N.

Expert Rev Neurother. 2016 Jun;16(6):625-33. doi: 10.1586/14737175.2016.1158102.

PMID:
26908168
8.

Effect of prior exposure to dopamine agonists on treatment with gabapentin enacarbil in adults with moderate-to-severe primary restless legs syndrome: pooled analyses from 3 randomized trials.

Ondo WG, Hermanowicz N, Borreguero DG, Jaros MJ, Kim R, Shang G.

J Clin Mov Disord. 2015 Mar 30;2:9. doi: 10.1186/s40734-015-0018-3. eCollection 2015.

9.

Frameless Stereotactic Robot-Assisted Subthalamic Nucleus Deep Brain Stimulation: Case Report.

Vadera S, Chan A, Lo T, Gill A, Morenkova A, Phielipp NM, Hermanowicz N, Hsu FP.

World Neurosurg. 2017 Jan;97:762.e11-762.e14. doi: 10.1016/j.wneu.2015.11.009. Epub 2015 Nov 14.

PMID:
26585721
10.

Parkinson's disease psychosis: symptoms, management, and economic burden.

Hermanowicz N, Edwards K.

Am J Manag Care. 2015 Aug;21(10 Suppl):s199-206. Review.

11.

Colorectal surgery in Parkinson's disease--outcomes and predictors of mortality.

Hwang GS, Young MT, Hanna MH, Menon G, Phelan M, Carmichael JC, Mills S, Stamos MJ, Hermanowicz N, Pigazzi A.

Int J Colorectal Dis. 2015 Aug;30(8):1051-8. doi: 10.1007/s00384-015-2256-0. Epub 2015 Jun 4.

12.

A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit.

Parkinson Study Group QE3 Investigators, Beal MF, Oakes D, Shoulson I, Henchcliffe C, Galpern WR, Haas R, Juncos JL, Nutt JG, Voss TS, Ravina B, Shults CM, Helles K, Snively V, Lew MF, Griebner B, Watts A, Gao S, Pourcher E, Bond L, Kompoliti K, Agarwal P, Sia C, Jog M, Cole L, Sultana M, Kurlan R, Richard I, Deeley C, Waters CH, Figueroa A, Arkun A, Brodsky M, Ondo WG, Hunter CB, Jimenez-Shahed J, Palao A, Miyasaki JM, So J, Tetrud J, Reys L, Smith K, Singer C, Blenke A, Russell DS, Cotto C, Friedman JH, Lannon M, Zhang L, Drasby E, Kumar R, Subramanian T, Ford DS, Grimes DA, Cote D, Conway J, Siderowf AD, Evatt ML, Sommerfeld B, Lieberman AN, Okun MS, Rodriguez RL, Merritt S, Swartz CL, Martin WR, King P, Stover N, Guthrie S, Watts RL, Ahmed A, Fernandez HH, Winters A, Mari Z, Dawson TM, Dunlop B, Feigin AS, Shannon B, Nirenberg MJ, Ogg M, Ellias SA, Thomas CA, Frei K, Bodis-Wollner I, Glazman S, Mayer T, Hauser RA, Pahwa R, Langhammer A, Ranawaya R, Derwent L, Sethi KD, Farrow B, Prakash R, Litvan I, Robinson A, Sahay A, Gartner M, Hinson VK, Markind S, Pelikan M, Perlmutter JS, Hartlein J, Molho E, Evans S, Adler CH, Duffy A, Lind M, Elmer L, Davis K, Spears J, Wilson S, Leehey MA, Hermanowicz N, Niswonger S, Shill HA, Obradov S, Rajput A, Cowper M, Lessig S, Song D, Fontaine D, Zadikoff C, Williams K, Blindauer KA, Bergholte J, Propsom CS, Stacy MA, Field J, Mihaila D, Chilton M, Uc EY, Sieren J, Simon DK, Kraics L, Silver A, Boyd JT, Hamill RW, Ingvoldstad C, Young J, Thomas K, Kostyk SK, Wojcieszek J, Pfeiffer RF, Panisset M, Beland M, Reich SG, Cines M, Zappala N, Rivest J, Zweig R, Lumina LP, Hilliard CL, Grill S, Kellermann M, Tuite P, Rolandelli S, Kang UJ, Young J, Rao J, Cook MM, Severt L, Boyar K.

JAMA Neurol. 2014 May;71(5):543-52. doi: 10.1001/jamaneurol.2014.131.

PMID:
24664227
13.

A synthetic cannabinoid agonist promotes oligodendrogliogenesis during viral encephalitis in rats.

Solbrig MV, Fan Y, Hermanowicz N, Morgese MG, Giuffrida A.

Exp Neurol. 2010 Nov;226(1):231-41. doi: 10.1016/j.expneurol.2010.09.003. Epub 2010 Sep 9.

14.

Inhibition of glyceraldehyde-3-phosphate dehydrogenase activity by antibodies present in the cerebrospinal fluid of patients with multiple sclerosis.

Kölln J, Zhang Y, Thai G, Demetriou M, Hermanowicz N, Duquette P, van den Noort S, Qin Y.

J Immunol. 2010 Aug 1;185(3):1968-75. doi: 10.4049/jimmunol.0904083. Epub 2010 Jul 7.

15.

Increased prevalence of val(66)met BDNF genotype among subjects with cervical dystonia.

Cramer SC, Sampat A, Haske-Palomino M, Nguyen S, Procaccio V, Hermanowicz N.

Neurosci Lett. 2010 Jan 1;468(1):42-5. doi: 10.1016/j.neulet.2009.10.059. Epub 2009 Oct 24.

16.

Orally disintegrating selegiline in Parkinson patients with dopamine agonist-related adverse effects.

Lyons KE, Friedman JH, Hermanowicz N, Isaacson SH, Hauser RA, Hersh BP, Silver DE, Tetrud JW, Elmer LW, Parashos SA, Struck LK, Lew MF, Pahwa R.

Clin Neuropharmacol. 2010 Jan-Feb;33(1):5-10. doi: 10.1097/WNF.0b013e3181b7926f.

PMID:
19855267
17.

A forty-five year follow-up EEG study of Qigong practice.

Qin Z, Jin Y, Lin S, Hermanowicz NS.

Int J Neurosci. 2009;119(4):538-52. doi: 10.1080/00207450802325520.

PMID:
19229721
18.

Cannabinoid rescue of striatal progenitor cells in chronic Borna disease viral encephalitis in rats.

Solbrig MV, Hermanowicz N.

J Neurovirol. 2008 May;14(3):252-60. doi: 10.1080/13550280802074521.

PMID:
18569459
19.

Fatal gastroparesis in a patient with Parkinson's disease.

Hermanowicz N.

Mov Disord. 2008 Jan;23(1):152-3. No abstract available.

PMID:
17987645
20.

Rasagiline as a therapy for Parkinson's disease (PD).

Hermanowicz N.

Am J Geriatr Pharmacother. 2007 Jun;5(2):174-5; author reply 175-6. No abstract available.

PMID:
17719520

Supplemental Content

Loading ...
Support Center